Diagnóstica Longwood
  • esES
  • +34 976 320 638
  • M-T: 8.30-17.30 F:8.30-14.30
  • Catalog
    • Immunology and transplantation
      • HLA Typing
      • Allergy
      • Alloantibodies Detection
      • HLA-associated diseases
      • Chimerism
      • Immune response and biomarkers
      • Immunosequencing
      • Other – Immunology
    • Molecular Genetics
      • Cystic Fibrosis
      • Prenatal Diagnosis
      • Reproduction
      • Pharmacogenomics
      • Triplet Expansion
      • Genetic Panels
      • Other – Genetics
    • Hematology and blood bank
      • Blood Group Genotyping (RBC)
      • Platelet Antibody Testing
      • Thrombophilias and Hemochromatosis
      • Cryopreservation
      • Other – Hematology
    • Oncology
      • Solid Tumor
      • Oncohematology
    • Microbiology
      • Fungus
      • Syndromic
      • Sepsis
      • NGS
    • Preanalytics
      • Blood collection
      • Sampling and Extraction
      • Sample transportation
  • Company
    • Contact
    • Work with us
    • Our brands
  • Events
Login

EndoPredict®

CatalogOncologySolid Tumor

Prognostic and predictive molecular in vitro test to determine the risk of recurrence and the absolute benefit of chemotherapy over the next 15 and 10 years, respectively, in patients with ER+/HER2- primary breast cancer.

EndoPredict is a prognostic and predictive in vitro molecular test for patients with ER+/HER2- (estrogen receptor positive, human epidermal growth factor receptor 2 negative) primary breast cancer.

This second generation test combines a molecular score, obtained from the analysis of the expression of 12 genes (8 genes relevant to the course of the disease, 3 normalization genes and a control gene), with tumour size and nodal status (negative: N0, or positive: N+), resulting in the "EPclin Risk Score". This score allows the establishment of a low-risk group or a high-risk group for recurrence.

By combining the molecular score with clinical parameters (tumour size and nodal status), a prognostic accuracy superior to that of first generation tests is achieved, and it is possible to determine the risk of recurrence and the absolute benefit of chemotherapy over the next 15 and 10 years, respectively.

In this way, EndoPredict answers 3 important clinical questions:

  • Can chemotherapy be avoided? - 10-year risk
REFERENCES: 1. Filipits M. et al.: Clin. Cancer Res. 2011, 2. Martin M. et al.: BCR 2014, 3. Buus et al.: J Natl Cancer Inst. 2016, 4. Sestak I. et al.: JAMA Oncol. 2018
  • What is the absolute benefit from chemotherapy at 10 years?
REFERENCES: 5. Sestak I. et al.: Breast Cancer Res Treat. 2019
  • Can endocrine therapy be stopped after 5 years? - Risk after 5 years and up to 15 years
REFERENCES: 6. Filipits M. et al.: Clin Cancer Res. 2019

EndoPredict is recommended by international guidelines such as ASCO, ESMO, St. Gallen, EGMT, AJCC, AGO or NCCN, is being validated in four large clinical studies (with more than 3,200 patients) and used to guide treatment selection in more than 30,000 patients worldwide.

Key features:

• It is the only test that provides answers to these three questions: Can chemotherapy be avoided? What is the absolute benefit of chemotherapy? Can endocrine therapy be stopped after 5 years?
• It is the test that provides the largest group of "true" low-risk patients
• Second generation test, achieving superior prognostic accuracy
• Unique gene selection for accurate short- and long-term risk assessment
• Consistent study cohorts and constant cut-off point
• Clear low and high risk categories
• Fast results: within 2 days by local testing

Options

Service with sample collection or lab kit (requires qPCR Quant Studio)

Public Documentation

  • EndoPredict General Flyer_EN_2019_V1
  • Comparative analysis EndoPredict Flyer_EN_2019_V1
  • EndoPredict_Case_Study_EN_2021_V7

Related products

myChoice CDx PLUS

La prueba más completa para determinar el estado de deficiencia de la recombinación homóloga (HDR) estudiando los genes BRCA y 13 más adicionales, en pacientes con cáncer de ovario.
  • Certificado CE
  • Certificado IVD

myChoice CDx

The most comprehensive tumor test to determine Homologous Recombination Deficiency (HDR) Status by studying the BRCA genes in patients with ovarian cancer.
  • Certificado CE
  • Certificado IVD

GeoMx Cancer Transcriptome Atlas (CTA)

Spatial study of the expression of over 1,800 genes involved in tumour biology, tumour microenvironment and immune response.
  • Certificado RUO
Oncología molecular

Oncology

Myriad Genetics
  • Certificado CE
  • Certificado IVD
  • RT-PCR
Request information - EndoPredict®

    Contact with the commercial department of Diagnóstica Longwood to request information and you will allow us to contact you commercially by email or telephone, complying with the European Data Protection regulations.

    You can unsubscribe when you want, rectify or limit your data.



    I consent to the use of my data to receive information and news

    In compliance with the provisions in the regulation General of protection of data 2016/679, DIAGNOSTICA LONGWOOD informs that its e-mail address, as well as other personal data that may be included in this form form part of a treatment of personal data whose features are detailed below: The controller of such processing will be DIAGNOSTICA LONGWOOD and the purpose will be to answer the queries raised by the user and to send him/her requested information, as well as to send information and news about our company, in case he/she has authorised it. By marking the consent, you are legitimising this use. DIAGNOSTICA LONGWOOD does not pass on data to third parties. You may at any time exercise your rights of access, rectification and deletion of your data, as explained in our Privacy Policy.


    Product families

    • Molecular Genetics
      • Prenatal Diagnosis
      • Triplet Expansion
      • Pharmacogenomics
      • Cystic Fibrosis
      • Other – Genetics
      • Genetic Panels
      • Reproduction
    • Hematology and blood bank
      • Platelet Antibody Testing
      • Cryopreservation
      • Blood Group Genotyping (RBC)
      • Other – Hematology
      • Thrombophilias and Hemochromatosis
    • Immunology and transplantation
      • Alloantibodies Detection
      • HLA-associated diseases
      • Immunosequencing
      • Other – Immunology
      • Chimerism
      • Immune response and biomarkers
      • HLA Typing
    • Microbiology
      • Fungus
      • NGS
      • Sepsis
      • Syndromic
    • Oncology
      • Oncohematology
      • Solid Tumor
    • Preanalytics
      • Sampling and Extraction
      • Blood collection
      • Sample transportation

    Diagnostica Longwood

    Customer Service:
    M-T 8.30 – 17.30 / F 8.30 – 14.30
    +34 976 320 638 – dlw@dlongwood.com

    • Quality Policy
    • Legal Warning
    • Privacy Policy
    • Cookie policy
    • Data Protection

    2021 © Diagnóstica Longwood SL

    We are using cookies to give you the best experience on our website.

    You can find out more about which cookies we are using or switch them off in settings.

    Powered by  GDPR Cookie Compliance
    Privacy Overview

    This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

    Strictly Necessary Cookies

    Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

    If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

    3rd Party Cookies

    This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

    Keeping this cookie enabled helps us to improve our website.

    Please enable Strictly Necessary Cookies first so that we can save your preferences!

    Política de cookies

    Más información sobre nuestra política de cookies